Patients Presenting With Reflux Symptoms - Whom to Test and Whom to Treat?

Noy Lapidot Alon, Tomas Navarro Rodriguez, Ronnie Fass
{"title":"Patients Presenting With Reflux Symptoms - Whom to Test and Whom to Treat?","authors":"Noy Lapidot Alon, Tomas Navarro Rodriguez, Ronnie Fass","doi":"10.7704/kjhugr.2025.0005","DOIUrl":null,"url":null,"abstract":"<p><p>Gastroesophageal reflux disease (GERD) is a complex condition with diverse clinical presentations, ranging from typical heartburn and regurgitation symptoms to extraesophageal manifestations and alarm symptoms. Determining which patients should be tested first versus those who should receive empirical treatment remains a key clinical challenge. If not recently performed, initial patient testing, commonly involving upper endoscopy, is recommended for patients presenting with alarm or refractory symptoms and for those at high risk for Barrett's esophagus. Additionally, testing should be prioritized for patients with underlying comorbidities, such as scleroderma, increased body mass index, or a suspected large hiatal hernia. Older patients with atypical symptom presentations and those with extraesophageal symptoms or signs, especially in the absence of typical GERD symptoms, should also be referred for endoscopy if recent endoscopic results are not available. In contrast, patients with typical GERD symptoms in the absence of alarm features and those with extraesophageal symptoms accompanied by typical GERD symptoms could begin empirical treatment with a proton pump inhibitor (PPI) or potassium competitive acid blocker (PCAB). For individuals without alarm symptoms who do not respond to once-daily PPI therapy, escalation to twice-daily PPI therapy or switching to a PCAB, without further testing, is appropriate. Overall, an individualized approach is recommended, with patient presentation guiding the decision to test or treat first.</p>","PeriodicalId":520887,"journal":{"name":"The Korean journal of helicobacter and upper gastrointestinal research","volume":"25 1","pages":"7-12"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12173587/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Korean journal of helicobacter and upper gastrointestinal research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7704/kjhugr.2025.0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Gastroesophageal reflux disease (GERD) is a complex condition with diverse clinical presentations, ranging from typical heartburn and regurgitation symptoms to extraesophageal manifestations and alarm symptoms. Determining which patients should be tested first versus those who should receive empirical treatment remains a key clinical challenge. If not recently performed, initial patient testing, commonly involving upper endoscopy, is recommended for patients presenting with alarm or refractory symptoms and for those at high risk for Barrett's esophagus. Additionally, testing should be prioritized for patients with underlying comorbidities, such as scleroderma, increased body mass index, or a suspected large hiatal hernia. Older patients with atypical symptom presentations and those with extraesophageal symptoms or signs, especially in the absence of typical GERD symptoms, should also be referred for endoscopy if recent endoscopic results are not available. In contrast, patients with typical GERD symptoms in the absence of alarm features and those with extraesophageal symptoms accompanied by typical GERD symptoms could begin empirical treatment with a proton pump inhibitor (PPI) or potassium competitive acid blocker (PCAB). For individuals without alarm symptoms who do not respond to once-daily PPI therapy, escalation to twice-daily PPI therapy or switching to a PCAB, without further testing, is appropriate. Overall, an individualized approach is recommended, with patient presentation guiding the decision to test or treat first.

出现反流症状的患者-谁该检查,谁该治疗?
胃食管反流病(GERD)是一种复杂的疾病,具有多种临床表现,从典型的胃灼热和反流症状到食管外表现和警报症状。确定哪些患者应该首先接受检测,哪些患者应该接受经验性治疗仍然是一个关键的临床挑战。如果最近没有进行过检查,建议对出现警报或难治性症状的患者以及Barrett食管高风险患者进行初步检查,通常包括上消化道内窥镜检查。此外,检测应优先考虑有潜在合并症的患者,如硬皮病、体重指数增加或疑似大裂孔疝。有非典型症状表现的老年患者和有食管外症状或体征的患者,特别是在没有典型胃反流症状的情况下,如果不能获得近期的内镜检查结果,也应转诊进行内镜检查。相比之下,没有报警特征的典型胃食管反流症状患者和伴有典型胃食管反流症状的食管外症状患者可以开始使用质子泵抑制剂(PPI)或竞争性钾酸阻滞剂(PCAB)进行经验性治疗。对于没有警示症状的个体,每日一次PPI治疗无效,可在不进一步检测的情况下,升级至每日两次PPI治疗或改用PCAB。总的来说,个体化的方法是推荐的,由病人的陈述来指导决定是先检查还是先治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信